Boundless Bio, Inc.
BOLD
Rank in Stocks
#22244
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing... Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
Share Price
$2.46
Last synced: 2026-11-09
Market Cap
$55.96M
Change (1 day)
0.00%
Change (1 year)
95.24%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Boundless Bio, Inc. (BOLD)
Category
Healthcare
EPS for Boundless Bio, Inc. (BOLD)
EPS as of June 2026 TTM: $-2.86
According to Boundless Bio, Inc.'s latest financial reports, its current EPS (TTM) is $-2.86. At the end of 2025 the company had an EPS of $-2.60, an increase over its 2024 EPS of $-3.85.
EPS history for Boundless Bio, Inc. from 2016 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-2.86 | 10.00% |
| 2025 | $-2.60 | -32.47% |
| 2024 | $-3.85 | 73.42% |
| 2023 | $-2.22 | 7.77% |
| 2022 | $-2.06 | 82.30% |
| 2021 | $-1.13 | -61.43% |
| 2018 | $-2.93 | -13.82% |
| 2017 | $-3.40 | -39.18% |
| 2016 | $-5.59 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -647.55% |
US
|
|
| $-7.07 | 147.20% |
US
|
|
| $-5.29 | 84.97% |
AU
|
|
| $12.88 | -550.35% |
BE
|
|
| $21.56 | -853.85% |
NL
|
Questions about Boundless Bio, Inc.'s earnings per share (EPS)
What is Boundless Bio, Inc.'s earnings per share (EPS)?
Boundless Bio, Inc.'s earnings per share (EPS) over the last twelve months is $-2.86, as of Jun 2026.
What was Boundless Bio, Inc.'s earnings per share (EPS) in 2025?
In 2025, Boundless Bio, Inc.'s earnings per share (EPS) was $-2.60, compared with $-3.85 in 2024.
How has Boundless Bio, Inc.'s earnings per share (EPS) changed since 2021?
From 2021 to 2025, Boundless Bio, Inc.'s earnings per share (EPS) was highest in 2021 ($-1.13) and lowest in 2024 ($-3.85).
How does Boundless Bio, Inc.'s earnings per share (EPS) compare with similar companies?
Boundless Bio, Inc.'s earnings per share (EPS) ($-2.86) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.